Podcasts about Lymphoma

This review series focuses on recent advances in resolving macro and molecular structures that have driven the field of occlusive thrombus structure and function forward. Covering multiple contributions to thrombosis, eg, platelets, factor XIII, and the contact system, the series also looks to put this new knowledge into the context of future advances in diagnostic and therapeutic tools to enhance normal hemostasis while preventing and treating unwanted thrombosis. Blood Associate Editor, Dr. Thomas Ortel discusses this series with Drs. Alisa Wolberg, Jonas Emsley, and John Weisel, who all contributed to articles in the Review Series on the Structural Underpinnings of Hemostatic Plugs and Thrombotic Occulsions which can be found in volume 146, issue 12 of Blood. 

During the 3pm hour of Chuck & Chernoff the guys broadcasted live from the Strikeout Leukemia and Lymphoma Radiothon at Beaver Toyotoa in Cumming. See omnystudio.com/listener for privacy information.

During the 4pm hour of Chuck & Chernoff the guys broadcasted live from the Strikeout Leukemia and Lymphoma Radiothon at Beaver Toyotoa in Cumming. See omnystudio.com/listener for privacy information.

During the 5pm hour of Chuck & Chernoff the guys broadcasted live from the Strikeout Leukemia and Lymphoma Radiothon at Beaver Toyotoa in Cumming. See omnystudio.com/listener for privacy information.

During the 2pm hour of Chuck & Chernoff the guys broadcasted live from the Strikeout Leukemia and Lymphoma Radiothon at Beaver Toyotoa in Cumming. See omnystudio.com/listener for privacy information.

In this episode of A Couple Takes on MS, we sit down with our pastor, Pastor Dana Hendershot, to talk about one of the biggest questions that can rise up after a diagnosis like MS (or cancer): Why did God let this happen? Dan reflects on 26 years since his MS diagnosis and how faith can change over time, not always through easy answers, but through presence, perspective, and community. Pastor Dana shares the moment her theology of suffering shifted, what she learned during her own cancer journey, and why it's okay to bring every emotion to God. Including anger. We talk about prayer as breath, the difference between “God caused this” and “God is with you in this,” why joy only exists in the present moment, and how hope sometimes looks like being carried by others when you can't carry yourself. In this episode, we get real with Pastor Dana about: • Where God is in diagnosis and suffering • Why it's OK to be angry with God (and why God can handle it) • Prayer as presence and the Spirit as the promise • Theology of the cross vs. theology of glory • Hope, community, and being carried when you're worn down • Finding joy right now and why singing can help shift your mind An open invitation for you, our listeners Where have you felt God's presence during a difficult season in your life? We'd love to hear from you at acoupletakesonms@gmail.com. About our guest: Pastor Dana Hendershot is an ordained pastor in the Evangelical Lutheran Church in America and has served as Senior Pastor of Immanuel Lutheran Church in Mount Pleasant, Michigan, since 2011. Dana holds a degree in psychology with a focus in neuropsychology and a Master of Divinity from the Lutheran School of Theology at Chicago, where her studies explored the intersection of science and faith. In addition to her congregational ministry, Dana serves as Chair of the Lutheran Alliance for Faith, Science, and Technology, helping lead national conversations about how theology, scientific discovery, and human curiosity connect. Her writing has appeared in Working Preacher, The Lutheran, and Lutheran Partners, where she brings thoughtful theology into everyday lived experience. In 2023, Dana was diagnosed with Large Cell B Non-Hodgkin's Lymphoma and underwent extensive treatment. That experience deepened her understanding of the body, vulnerability, and what it means to show up for others with compassion and presence. Dana has also been deeply involved in community advocacy. She helped establish Mount Pleasant's first rotating homeless shelter—Isabella County Restoration House—serves on Central Michigan University's Institutional Review Board, and previously served on the Interfaith Action of Southwest Florida Board of Directors while advocating for farmworker justice alongside the Coalition of Immokalee Workers. *** Remember to rate, review and subscribe to A Couple Takes on MS Podcast for two insightful perspectives on this one multifaceted disease.

Stefan Barta, MD, MS Cutaneous T‑cell lymphoma (CTCL) is a rare condition that often raises important questions for patients and families. In this episode, we sit down with Dr. Stefan Barta, of the University of Pennsylvania, to bring clarity to what CTCL is, how it's diagnosed, and what patients can expect from staging and treatment. Dr. Barta breaks down the differences between CTCL subtypes, explains why diagnosing someone can take time, and shares the most up-to-date therapies, including skin directed treatments, immunotherapies, and emerging clinical trial options. Most importantly, he offers reassurance for those newly diagnosed: “The future is absolutely bright… there is a lot of hope for our patients with CTCL.” DOWNLOAD TRANSCRIPT CLICK HERE to participate in our episode survey. Mentioned on this episode: Cutaneous T-cell lymphoma Cutaneous Lymphoma Foundation Clinical Trial Support Center Additional Blood Cancer United Support Resources: Free Nutrition Consultations Information Specialists Financial support Online Chat Free telephone/web patient programs Free booklets Young Adult Resources Support groups Caregiver support Caregiver Workbook Survivorship Workbook Advocacy and Public Policy Patient Community Mental Health Resources Episode supported by Kyowa Kirin, Inc. and Cutaneous Lymphoma Foundation.The post Cutaneous T-Cell Lymphoma (CTCL): Illuminating a Brighter Path Forward first appeared on The Bloodline with Blood Cancer United Podcast.

In this week's episode, Blood editor Dr. Laurie Sehn interviews authors Drs. Anastasios Karadimitris and Maria Carolina Florian on their papers published in Volume 147 Issue 2 of Blood. Dr. Karadimitris' paper "Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia", discusses the success of bispecific CAR-iNKT cells targeting CD19 and CD133 in pre-clinical models, prompting the clinical development of this class of product. Dr. Florian's paper, "A Notch trans-activation to cis-inhibition switch underlies hematopoietic stem cell aging" proposes that the Jagged2/Notch interaction is a key regulator of hematopoietic stem cell divisional symmetry during aging and offers insights that may inform strategies to restore regenerative function in aged hematopoiesis. 

Send a textMorning Prayer (Offer Your Body As Living Sacrifice; Leukemia & Lymphoma; Do All In Name of Jesus Giving Thanks To God)Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peace aimingforjesus.com YouTube Channel https://www.youtube.com/@aimingforjesus5346 Instagram https://www.instagram.com/aiming_for_jesus/ Threads https://www.threads.com/@aiming_for_jesus X https://x.com/AimingForJesus Tik Tok https://www.tiktok.com/@aiming.for.jesus

When sudden, severe abdominal pain led to a diagnosis of an aggressive and rare "double‑hit" lymphoma, Ted Wagstaff found himself facing the unthinkable. Pulse follows Ted's journey through intensive, highly personalized treatment at The Ottawa Hospital, guided by hematologist Dr. Kevin Imrie and a collaborative team determined to outpace a fast‑moving disease. 

In this week's episode, Blood editor Dr. James Griffin interviews Drs. Paresh Vyas and Andrew Hantel on their research published in this week's issue of Blood. Dr. Vyas discusses his paper, "Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy", which provided new insights as to when and how to intervene to circumvent resistance to AML remission. Dr. Hantel will speak about his paper, "Impact of Modernizing Eligibility Criteria on Enrollment and Representation in AML Clinical Trials". For a real-world cohort of more than 2200 patients with AML, they reported that modernized, safety-based criteria could nearly double trial eligibility, with especially pronounced gains among historically underserved groups.  Both studies highlight how biologic insight and thoughtful trial design can drive more effective, inclusive advances in AML treatment and research. 

In today's episode, our discussion features Tycel Phillips, MD. Dr Phillips is an associate professor in the Department of Hematology and Hematopoietic Cell Transplantation in the Division of Lymphoma at City of Hope in Duarte, California.In our exclusive interview, Dr Phillips discussed updated efficacy and safety data from the phase 2 EPCORE NHL-1 trial (NCT03625037) investigating epcoritamab-bysp (Epkinly) monotherapy in patients with relapsed/refractory large B-cell lymphoma (LBCL). He noted that the data, which were presented at the 2025 ASH Annual Meeting, showed that several patients remained in response beyond 4 years, and that no new major safety signals were reported. Overall, he highlighted that the trial findings continue to support the use of epcoritamab as a third-line, potentially curative option for patients with LBCL. He also spotlighted the promise of synergistic polatuzumab vedotin-piiq (Polivy)–based combinations in the management of non-Hodgkin lymphoma.

In this week's episode, Blood Associate editor Dr. Hervé Dombret interviews authors Drs. Sarah K. Tasian and David T. Teachey on their contributions to the How I Treat Series on acute lymphoblastic leukemia. Dr. Tasian's paper, “How I treat Philadelphia chromosome-like acute lymphoblastic leukemia in children, adolescents, and young adults” discusses the different classes of Ph-like ALL and reviews the recent trials investigating TKIs and immunotherapy specifically for this high-risk patient population. Dr. Teachey's paper, “How I treat ETP-ALL in children”, discusses the best current and emerging therapies that may be used in patients with ETP ALL, including nelarabine and other new agents, immunotherapy, and allogeneic HSCT.See the full How I Treat series in volume 145 issue 1 of Blood.

In this episode of TheHemOnc Pulse, Rahul Banerjee, MD, speaks with Francine Foss, MD, professor of medicine and dermatology at Yale School of Medicine, about the evolving landscape of T-cell lymphomas. Dr Foss discusses the unique challenges of studying and treating rare diseases such as cutaneous T-cell lymphoma and explains why real-world data are essential to closing evidence gaps. The conversation highlights the role of collaborative registries in tracking treatment patterns, outcomes, and access to care across community and academic settings. Dr Foss also shares how both clinicians and patients can participate in these efforts to strengthen research, inform future clinical trials, and improve outcomes for patients with T-cell lymphomas.

To have Dr. Morse answer a question, visit: https://drmorses.tv/ask/ All of Dr. Morse's and his son's websites under one roof: https://handcrafted.health/ Facebook Page: https://www.facebook.com/handcrafted.health 00:00:00 - Intro - New Classes - Formulas 00:16:14 - Burkitt Lymphoma  00:46:14 - Slurred Speech 01:01:04 - Mold 01:09:35 - Eye Pictures 01:21:45 - Anhedonia - Headaches - Brain Fog - Bloating - IBS 01:35:15 - Breast Lump 00:16:14 - Burkitt Lymphoma We would really appreciate guidance on how best to support her body following chemotherapy. 00:46:14 - Slurred Speech I'm having memory issues, and slurred speech at times. 01:01:04 - Mold I'm reaching out because I've been very sick after long-term exposure to mold in my previous home.  01:09:35 - Eye Pictures Can you explain more about brown eyes and the varying degrees of lymph stagnation?  01:21:45 - Anhedonia - Headaches - Brain Fog - Bloating - IBS I'm numb to everything, even to food I eat. I feel no emotions at all. 01:35:15 - Breast Lump We would like to bring the case of our 16-year-old daughter.

BloodCancerTalks: ASH 2025 Lymphoma RoundupGuest: Dr. Carla Casulo, Associate Professor, Wilmot Cancer Centre, University of RochesterAbstracts DiscussedFollicular LymphomaEPCORE-FL1 (Falchi) - Epcoritamab plus lenalidomide-rituximab (R2) in relapsed/refractory FLTheme: Bispecific antibody combinations in R/R FL; comparing to other approaches Diffuse Large B-Cell Lymphoma (DLBCL) - Elderly/Unfit PatientsMorningSun (Sharman) - Mosunetuzumab monotherapy in patients ≥80 years or chemo-ineligibleEPCOR-DLBCL-3 (Vitolo) - Epcoritamab monotherapy in elderly patientsR-Pola-Glo - Rituximab-polatuzumab-glofitamab combination in older/frail patientsTheme: Single-agent and combination bispecific strategies for elderly and frail DLBCL patients DLBCL - First-Line TreatmentSMART STOP (Westin) - Chemotherapy-free approach using lenalidomide, tafasitamab, rituximab, acalabrutinib (ULTRA regimen)FrontMIND - Tafasitamab-lenalidomide added to R-CHOPTheme: Chemotherapy-sparing and chemo-intensification strategies in newly diagnosed DLBCL DLBCL - Relapsed/RefractoryDALY 2-EU (Borchmann) - Dual CD19/CD20 CAR-T (zamto-cel) versus R-GemOx in transplant-ineligible patientsTheme: Expanding CAR-T eligibility; treatment selection in transplant-ineligible R/R DLBCL Hodgkin LymphomaSWOG 1826 - 3-year update: Nivolumab-AVD versus brentuximab-AVDHD21 - 5-year update: PET-adapted BrECADD versus BEACOPPTheme: Long-term outcomes and treatment selection in newly diagnosed Hodgkin lymphoma Burkitt LymphomaZUMA-25 (Van Dorp) - Brexucabtagene autoleucel (Brexu-cel) in relapsed/refractory BurkittTheme: CAR-T therapy for the challenging population of R/R Burkitt lymphoma Mantle Cell Lymphoma - First-Line TrAVeRse - Acalabrutinib, venetoclax, rituximabGLOVe - Glofitamab, lenalidomide, venetoclax (high-risk MCL)BOVen - Zanubrutinib, obinutuzumab, venetoclax (older patients)MAVO - Acalabrutinib, venetoclax, obinutuzumabWindow-3 - Acalabrutinib-rituximab followed by brexu-cel (high-risk MCL)Theme: Chemotherapy-free combinations in newly diagnosed mantle cell lymphoma

Featuring perspectives from Prof Michael Dickinson and Dr Laurie H Sehn, including the following topics:  Introduction (0:00) Future Treatment of Non-Hodgkin Lymphoma (NHL) (2:24) Case: A man in his mid 60s with diffuse large B-cell lymphoma (DLBCL) and early relapse on axicabtagene ciloleucel receives glofitamab — Dr Sehn (8:10) Case: A man in his late 60s with Type 2 diabetes, congestive heart failure and chronic obstructive pulmonary disease receives glofitamab monotherapy after glofitamab with gemcitabine/oxaliplatin for relapsed GCB-type double-hit DLBCL — Matthew Lunning, DO (14:54) Practical Perspectives on the Current Role of Bispecific Antibodies in the Management of Lymphoma — Prof Dickinson (18:00) Case: A woman in her mid 50s with multiregimen-recurrent follicular lymphoma (FL) receives mosunetuzumab — Carla Casulo, MD (35:33) Case: A man in his late 70s with multiregimen-refractory FL receives mosunetuzumab with an ongoing complete response — Dr Sehn (40:05) FL and Other NHL Subtypes — Dr Sehn (45:30) CME information and select publications

Prof Michael Dickinson from Peter MacCallum Cancer Centre in Melbourne, Australia, and Dr Laurie H Sehn from the University of British Columbia in Vancouver, Canada, discuss clinical cases and recent findings from the 2025 ASH Annual Meeting relating to the use of bispecific antibodies in the management of lymphoma.CME information and select publications here.

Show notes and links: www.chrisbeatcancer.com/how-carl-mason-healed-stage-iv-lymphoma-after-treatment-failed

In this week's episode, Blood Associate editor Dr. Thomas Ortel interviews authors Drs. Ware Branch and J.J. Strouse on their contributions to How I Treat hematologic complications in pregnancy. Dr. Branch's paper, “How I diagnose and treat antiphospholipid syndrome in pregnancy” discusses the evolving clinical and laboratory features of APS, and the treatment of cases meeting ACR/EULAR classification criteria. Dr. Strouse stresses the unique problems posed to both the mother and fetus during pregnancy in his paper "How I treat sickle cell disease in pregnancy”.See the full How I Treat series in volume 143 issue 9 of Blood journal. 

In this episode of the Oncology Brothers podcast, we were joined by Dr. Julie Vose, a leading expert in lymphoma from the University of Nebraska Medical Center. Together, we delved into the key abstracts presented at ASH 2025, focusing on significant studies in lymphoma and chronic lymphocytic leukemia (CLL). Episode Highlights: ● EPCORE FL-1: the approval of Epcoritamab in combination with Rituximab and lenalidomide for relapsed refractory follicular lymphoma ● CLL-17: comparison between continuous BTK inhibitors and fixed-duration venetoclax with obinutuzumab ● BRUIN CLL-313: insights into the non-covalent BTK inhibitor, pirtobrutinib, and its effectiveness in the frontline setting compared to traditional treatments ● S1826: a three-year update on the use of Nivolumab-AVD versus BV-AVD in advanced-stage Hodgkin's lymphoma, showcasing improved PFS and better tolerability Join us as we unpack these practice-changing studies and discuss their implications for community oncologists. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more insights and highlights from oncology conferences! #ASH25 #Oncology #Hematology #Lymphoma #CLL #CancerResearch

This week's episode accompanies the Review Series on Marginal Zone Lymphoma published in this week's issue of Blood. Associate editor, Dr. Philippe Armand interviews authors Dr. Juan Pablo Alderuccio and Dr. Ariela Noy on their contribution to this review series titled "The treatment of marginal zone lymphoma". The article is crucial in highlighting the clinically and biologically heterogenous nature of MZL diseases, and how current treatment options and available research do not allow for comprehensive MZL specific therapies. Drs. Alderuccio and Noy share their insights on specific avenues for the expansion of the MZL care landscape. Find the full review series in volume 147 issue 2 of Blood journal.

In this week's episode we've pulled a vault recording from 2025! Blood editor Dr. Laurie Sehn interviews authors Drs. David-Alexandre Trégouët and Johannes Schetelig on their research published in volume 146 issue 19 of Blood journal. Dr. Trégouët's study conducted a genome-wide association study supplemented by transcriptome and Mendelian randomization analyses to identify 28 loci and proteins associated with VTE recurrence risk. This work provides genomic evidence that inherited variants contribute to the risk of VTE recurrence, raising the possibility of a more personalized approach to the prevention of recurrent VTE. The study conducted by Dr. Schetelig and colleagues report the results of a long term trial on patients with poor-response AML, comparing outcomes between patients who received salvage chemotherapy versus immediate transplantation. With no difference in survival rates at 5 years, outcomes seem to be determined mainly by genetic risk factors, age, and comorbidities, therefore challenging the routine use of intensive remission induction before allogeneic transplant in patients with an available donor and underscore the need for novel therapeutic strategies for poor-risk AML.Featured Articles:Molecular Determinants of Thrombosis Recurrence Risk Across Venous Thromboembolism Subtypes Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial 

In today's episode, the discussion features Joanna M. Rhodes, MD, MSCE, director of Lymphoma and systems head for Lymphoma at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health, alongside Krish Patel, MD, director of Lymphoma Research and executive chair of the Lymphoma Research Executive Committee at the Sarah Cannon Research Institute. Together, they discussed how the chronic lymphocytic leukemia (CLL) treatment paradigm continues to evolve with advances in targeted therapy. In this exclusive interview, Drs Rhodes and Patel highlighted key disease- and patient-related factors that guide first-line treatment selection, considerations that influence sequencing decisions in later lines of therapy, and how hematologists determine the optimal timing to transition between treatments. They also discussed the clinical distinctions between covalent and noncovalent BTK inhibitors, the current role of pirtobrutinib (Jaypirca) in CLL management, and how its safety profile and emerging data may inform future use earlier in the treatment course. The conversation concluded with reflections on the CLL data presented at the 2025 ASH Annual Meeting that were most relevant to clinical practice. nd many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

When it comes to your pet's health, there is no word more terrifying than "cancer." The immediate reaction is often fear, followed by a difficult question: "I wouldn't put myself through chemo, so why would I put my dog through it?"In this episode, we sit down with Dr. Rance Gamblin, a veterinary oncologist formerly at Metropolitan Veterinary Hospital and now professor at Mississippi State College of Veterinary Medicine with 24+ years of experience and a calming presence that could soothe even the most "OCD" pet parent (just ask Alice!). Dr. Gamblin helps us navigate the emotional and medical complexities of a cancer diagnosis, explaining why veterinary oncology is often far more compassionate and focused on quality of life than human medicine.In this episode, we discuss:- The "Quality of Life" Philosophy: Why the goals of pet oncology differ from human oncology—focusing on making pets feel better for longer, rather than "curing at any cost."- Common Culprits: A look at the most frequent cancers Dr. Gamblin treats, including Lymphoma, Mast Cell Tumors, and Osteosarcoma.- The Truth About Side Effects: Do dogs lose their hair? Dr. Gamblin shares the reality of how pets handle chemotherapy (hint: there's a lot more tail-wagging involved than you'd think).- Treatment Innovations: Insights into the Yale vaccine study and the fascinating science behind the Melanoma vaccine. -Proactive Pet Parenting: Why Dr. Gamblin's biggest pet peeve is the "let's just watch it" approach, and why your pet's breath or a quick rectal exam could be a lifesaver.- Knowing When It's Time: A heart-to-heart on the "Big Four" indicators of quality of life and how to navigate the toughest decision a pet owner can make.Dr. Rance Gamblin earned his BS in Biology from Mississippi State and completed his residency in Oncology and Hematology at The Ohio State University. For over two decades, he has been a pillar of the veterinary community at Metropolitan Veterinary Hospital, known for his expertise, his steady hand, and an accent you'll just have to hear for yourself to guess where he's from! He is currently a professor at Mississippi State College of Veterinary Medicine.--What started during the COVID-19 lockdown with one baby gorilla at the Cleveland Zoo has grown into a channel loved by animal fans around the world. I'm a one-person operation—filming, editing, narrating, and sharing the most heartfelt moments of baby gorillas, orangutans, elephants, and other zoo animals. Whether it's Jameela's emotional journey or Clementine's first steps, each video brings you closer to the animals and their stories. If you love watching real animal behavior, learning fun facts, and supporting conservation through storytelling—this is your place! Subscribe to Larry's Animal Safari on YouTube @larrysanimalsafari ---Support our sponsor for this episode Blue Buffalo by visiting bluebuffalo.com. BLUE Natural Veterinary Diet formulas offer the natural alternative in nutritional therapy. At Blue Buffalo, we have an in-house Research & Development (R&D) team with over 300 years' experience in well-pet and veterinary therapeutic diets, over 600 scientific publications, and over 50 U.S. patents. At Blue Buffalo, we have an in-house Research & Development (R&D) team with over 300 years' experience in well-pet and veterinary therapeutic diets, over 600 scientific publications, and over 50 U.S. patents.---All footage is owned by SLA Video Productions.

When it comes to your pet's health, there is no word more terrifying than "cancer." The immediate reaction is often fear, followed by a difficult question: "I wouldn't put myself through chemo, so why would I put my dog through it?"In this episode, we sit down with Dr. Rance Gamblin, a veterinary oncologist formerly at Metropolitan Veterinary Hospital and now professor at Mississippi State College of Veterinary Medicine with 24+ years of experience and a calming presence that could soothe even the most "OCD" pet parent (just ask Alice!). Dr. Gamblin helps us navigate the emotional and medical complexities of a cancer diagnosis, explaining why veterinary oncology is often far more compassionate and focused on quality of life than human medicine.In this episode, we discuss:- The "Quality of Life" Philosophy: Why the goals of pet oncology differ from human oncology—focusing on making pets feel better for longer, rather than "curing at any cost."- Common Culprits: A look at the most frequent cancers Dr. Gamblin treats, including Lymphoma, Mast Cell Tumors, and Osteosarcoma.- The Truth About Side Effects: Do dogs lose their hair? Dr. Gamblin shares the reality of how pets handle chemotherapy (hint: there's a lot more tail-wagging involved than you'd think).- Treatment Innovations: Insights into the Yale vaccine study and the fascinating science behind the Melanoma vaccine. -Proactive Pet Parenting: Why Dr. Gamblin's biggest pet peeve is the "let's just watch it" approach, and why your pet's breath or a quick rectal exam could be a lifesaver.- Knowing When It's Time: A heart-to-heart on the "Big Four" indicators of quality of life and how to navigate the toughest decision a pet owner can make.Dr. Rance Gamblin earned his BS in Biology from Mississippi State and completed his residency in Oncology and Hematology at The Ohio State University. For over two decades, he has been a pillar of the veterinary community at Metropolitan Veterinary Hospital, known for his expertise, his steady hand, and an accent you'll just have to hear for yourself to guess where he's from! He is currently a professor at Mississippi State College of Veterinary Medicine.--What started during the COVID-19 lockdown with one baby gorilla at the Cleveland Zoo has grown into a channel loved by animal fans around the world. I'm a one-person operation—filming, editing, narrating, and sharing the most heartfelt moments of baby gorillas, orangutans, elephants, and other zoo animals. Whether it's Jameela's emotional journey or Clementine's first steps, each video brings you closer to the animals and their stories. If you love watching real animal behavior, learning fun facts, and supporting conservation through storytelling—this is your place! Subscribe to Larry's Animal Safari on YouTube @larrysanimalsafari ---Support our sponsor for this episode Blue Buffalo by visiting bluebuffalo.com. BLUE Natural Veterinary Diet formulas offer the natural alternative in nutritional therapy. At Blue Buffalo, we have an in-house Research & Development (R&D) team with over 300 years' experience in well-pet and veterinary therapeutic diets, over 600 scientific publications, and over 50 U.S. patents. At Blue Buffalo, we have an in-house Research & Development (R&D) team with over 300 years' experience in well-pet and veterinary therapeutic diets, over 600 scientific publications, and over 50 U.S. patents.---All footage is owned by SLA Video Productions.

Send us a textMORNING PRAYERS (Praise to God; Leukemia, Lymphomas, Multiple Myeloma; Salvation) #prayer #morningprayer #pray #jesus #god #holyspirit #aimingforjesus #healing #peace #love #bible #praise #praisegod #leukemia #lymphoma #hodgkinslymphomaawareness #nonhodgkinslymphoma #multiplemyeloma #salvation #bornagain Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peace aimingforjesus.com YouTube Channel https://www.youtube.com/@aimingforjesus5346 Instagram https://www.instagram.com/aiming_for_jesus/ Threads https://www.threads.com/@aiming_for_jesus X https://x.com/AimingForJesus Tik Tok https://www.tiktok.com/@aiming.for.jesus

In this week's episode, Blood editor Dr. James Griffin interviews authors Drs. Vincent Muczynski and Mark Geyer on their latest research published in Blood. Dr. Muczynski's research asks if there could there be a better gene than the factor VIII (FVIII) gene to transfer for curative treatment of hemophilia A? Dr. Geyer then explores CAR T cells armed with interleukin-18 (IL-18) secretion that target CD371, a transmembrane glycoprotein with high expression on AML and leukemia-initiating cells. Both studies explore finding novel targets for these powerful treatment modalities. Featured Articles:Alternative AAV gene therapy for hemophilia A using expression of Bi8, a novel single-chain FVIII-mimetic antibodyCD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia

In this podcast episode, Jeremy S. Abramson, MD, MMSc, reviews data from select presentations in lymphomas at the ASH 2025 Annual Meeting and provides perspectives on the clinical implications of these data for patients with chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL), including:CLL17: randomized phase III trial of continuous ibrutinib vs fixed-duration venetoclax plus obinutuzumab or venetoclax plus ibrutinib for untreatedCLL BRUIN CLL-313: randomized phase III trial of pirtobrutinib vs BR for previously untreated patients with CLLBRUIN CLL-314: pirtobrutinib vs ibrutinib in treatment-naive and BTKi-naive R/R CLL/SLL EPCORE-FL-1: randomized phase III trial of epcoritamab with rituximab and lenalidomide vs rituximab and lenalidomide for R/R FLSTARGLO: 3-year follow-up data from the randomized phase III trial of glofitamab plus GemOx vs rituximab plus GemOx for patients with R/R DLBCLPresenter: Jeremy S. Abramson, MD, MMScProfessor of MedicineHarvard Medical SchoolDirector, Center for LymphomaMass General Brigham Cancer InsBoston, MassachusettsContent based on an online CME program supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.Link to full program:https://bit.ly/4aqMobZ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The benefits of sauna and sunlight during winter monthsApplied Behavioral Analysis in autism treatmentWhat are good supplements to take for HPV virus?

I was diagnosed with follicular lymphoma, but my symptoms may be caused by something else, per my oncologistI've been taking acidophilus and eating yogurt, but still have diarrhea for the last five months since taking a round of antibioticsThe consequences of antibiotic useMy carotid artery intima-media thickness shows higher than normal thickness. Should I be concerned?

In this week's episode, Blood editor Dr. Laurie Sehn interviews three of the latest Blood authors: Drs. Vijay Sankaran, Ruud Delwel, Françoise Kraeber-Bodere. Two studies on the MECOM gene have been paired in this episode, analyzing new groundwork for potential novel myeloid differentiation therapies via repression of MECOM restoring enhancer mediated CEBPA expression. We'll also hear about the results of CASSIOPET, imaging companion study of the CASSIOPEIA trial, and how achieving negativity in PET before starting maintenance therapy is significant even in patients who still show residual disease in the bone marrow.Featured ArticlesCEBPA repression by MECOM blocks differentiation to drive aggressive leukemiasMECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed from the CASSIOPEIA trial

- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on Leukemia, Lymphoma, Multiple Myeloma, & Myeloproliferative Neoplasms (MPN) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team about Quality-of-Life Concerns - Questions for Our Panel of Expert Speakers

- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on Leukemia, Lymphoma, Multiple Myeloma, & Myeloproliferative Neoplasms (MPN) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team about Quality-of-Life Concerns - Questions for Our Panel of Expert Speakers

- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on Leukemia, Lymphoma, Multiple Myeloma, & Myeloproliferative Neoplasms (MPN) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team about Quality-of-Life Concerns - Questions for Our Panel of Expert Speakers

The lymphatic system, or lymphoid system, is one of the components of the circulatory system, and it serves a critical role in both immune function and surplus extracellular fluid drainage.  Components of the lymphatic system include lymph, lymphatic vessels and plexuses, lymph nodes, lymphatic cells, and a variety of lymphoid organs. The pattern and form of lymphatic channels are more variable and complex but generally parallel those of the peripheral vascular system. The lymphatic system partly functions to convey lymphatic fluid, or lymph, through a network of lymphatic channels, filter lymphatic fluid through lymph nodes and return lymphatic fluid to the bloodstream, where it is eventually eliminated. Nearly all body organs, regions, and systems have lymphatic channels to collect the various byproducts that require elimination . Liver and intestinal lymphatics produce about 80% of the volume of lymph in the body. Notable territories of the body that do not appear to contain lymphatics include the bone marrow, epidermis, as well as other tissues where blood vessels are absent. The central nervous system was long considered to be absent of lymphatic vessels until they were recently identified in the cranial meninges. Moreover, a vessel appearing to have lymphatic features was also discovered in the eye. The lymphatic system is critical in a clinical context, particularly given that it is a major route for cancer metastasis and that the inflammation of lymphatic vessels and lymph nodes is an indicator of pathology.  Structure The lymphatic system includes numerous structural components, including lymphatic capillaries, afferent lymphatic vessels, lymph nodes, efferent lymphatic vessels, and various lymphoid organs.  Lymphatic capillaries are tiny, thin-walled vessels that originate blindly within the extracellular space of various tissues. Lymphatic capillaries tend to be larger in diameter than blood capillaries and are interspersed among them to enhance their ability to collect interstitial fluid efficiently. They are critical in the drainage of extracellular fluid and allow this fluid to enter the closed capillaries but not exit due to their unique morphology. Lymphatic capillaries at their blind ends are composed of a thin endothelium without a basement membrane. The endothelial cells at the closed end of the capillary overlap but shift to open the capillary end when interstitial fluid pressure is greater than intra-capillary pressure. This process permits lymphocytes, interstitial fluid, bacteria, cellular debris, plasma proteins, and other cells to enter the lymphatic capillaries. Special lymphatic capillaries called lacteals exist in the small intestine to contribute to the absorption of dietary fats. Lymphatics in the liver contribute to a specialized role in transporting hepatic proteins into the bloodstream. The lymphatic capillaries of the body form large networks of channels called lymphatic plexuses and converge to form larger lymphatic vessels. Lymphatic vessels convey lymph, or lymphatic fluid, through their channels. Afferent (toward) lymphatic vessels convey unfiltered lymphatic fluid from the body tissues to the lymph nodes, and efferent (away) lymphatic vessels convey filtered lymphatic fluid from lymph nodes to subsequent lymph nodes or into the venous system. The various efferent lymphatic vessels in the body eventually converge to form two major lymphatic channels: the right lymphatic duct and the thoracic duct.  The right lymphatic duct drains most of the right upper quadrant of the body, including the right upper trunk, right upper extremity, and right head and neck. The right lymphatic trunk is a visible channel in the right cervical region just anterior to the anterior scalene muscle. Its origin and termination are variable in morphology, typically forming as the convergence of the right bronchomediastinal, jugular, and subclavian trunks, extending 1 to 2 centimeters in length before returning its contents to the systemic circulation at the junction of the right internal jugular, subclavian, and/or brachiocephalic veins.  The thoracic duct, also known as the left lymphatic duct or van Hoorne's canal, is the largest of the body's lymphatic channels. It drains most of the body except for the territory of the right superior thorax, head, neck, and upper extremity served by the right lymphatic duct. The thoracic duct is a thin-walled tubular vessel measuring 2 to 6 mm in diameter. The length of the duct ranges from 36 to 45 cm. The thoracic duct is highly variable in form but typically arises in the abdomen at the superior aspect of the cisterna chyli, around the level of the twelfth thoracic vertebra (T12). The cisterna chyli, from which it extends, is an expanded lymphatic sac that forms at the convergence of the intestinal and lumbar lymphatic trunks extending along the L1-L2 vertebral levels. The cisterna chyli is present in approximately 40-60% of the population, and in its absence, the intestinal and lumbar lymphatic trunks communicate directly with the thoracic duct at the T12 level. As a result, the thoracic duct receives lymphatic fluid from the lumbar lymphatic trunks and chyle, composed of lymphatic fluid and emulsified fats, from the intestinal lymphatic trunk. Initially, the thoracic duct is located just to the right of the midline and posterior to the aorta. It exits the abdomen and enters the thorax via the aortic hiatus formed by the right and left crura of the diaphragm, side by side with the aorta. The thoracic duct then ascends in the thoracic cavity just anterior and to the right of the vertebral column between the aorta and azygos vein. At about the level of the fifth thoracic vertebra (T5), the thoracic duct typically crosses to the left of the vertebral column and posterior to the esophagus. From here, it ascends vertically and usually empties its contents into the junction of the left subclavian and left internal jugular veins in the cervical region. To ensure that lymph does not flow backward, collecting lymphatic vessels and larger lymphatic vessels have one-way valves. These valves are not present in the lymphatic capillaries. These lymphatic valves permit the continued advancement of lymph through the lymphatic vessels aided by a pressure gradient created by vascular smooth muscle, skeletal muscle contraction, and respiratory movements. However, it is important to note that lymphatic vessels also communicate with the venous system through various anastomoses. Lymph nodes are small bean-shaped tissues situated along lymphatic vessels. Lymph nodes receive lymphatic fluid from afferent lymphatic vessels and convey lymph away through efferent lymphatic vessels. Lymph nodes serve as a filter and function to monitor lymphatic fluid/blood composition, drain excess tissue fluid and leaked plasma proteins, engulf pathogens, augment an immune response, and eradicate infection. Several organs in the body are considered to be lymphoid or lymphatic organs, given their role in the production of lymphocytes. These include the bone marrow, spleen, thymus, tonsils, lymph nodes, and other tissues. Lymphoid organs can be categorized as primary or secondary lymphoid organs. Primary lymphoid organs are those that produce lymphocytes, such as the bone marrow and thymus. Bone marrow is the primary site for the production of lymphocytes. The thymus is a glandular organ located anterior to the pericardium. It serves to mature and develop T cells, or thymus cell lymphocytes, in response to an inflammatory process or pathology. As individuals age, both their bone marrow and thymus reduce and accumulate fat. Secondary lymphoid organs serve as territories in which immune cells function and include the spleen, tonsils, lymph nodes, and various mucous membranes, such as in the intestines. The spleen is a purplish, fist-sized organ in the left upper abdominal quadrant that contributes to immune function by serving as a blood filter, storing lymphocytes within its white pulp, and being a site for an adaptive immune response to antigens. The lingual tonsils, palatine tonsils, and pharyngeal tonsils, or adenoids, work to prevent pathogens from entering the body. Mucous membranes in the gastrointestinal, respiratory, and genitourinary systems also function to prevent pathogens from entering the body. Lymph Lymphatic fluid, or lymph, is similar to blood plasma and tends to be watery, transparent, and yellowish in appearance. Extracellular fluid leaks out of the blood capillary walls because of pressure exerted by the heart or osmotic pressure at the cellular level. As the interstitial fluid accumulates, it is picked up by the tiny lymphatic capillaries along with other substances to form lymph. This fluid then passes through the lymphatic vessels and lymph nodes and finally enters the venous circulation. As the lymph passes through the lymph nodes, both monocytes and lymphocytes enter it.  Lymph is composed primarily of interstitial fluid with variable amounts of lymphocytes, bacteria, cellular debris, plasma proteins, and other cells. In the GI tract, lymphatic fluid is called chyle and has a milk-like appearance that is chiefly due to the presence of cholesterol, glycerol, fatty acids, and other fat products. The vessels that transport the lymphatic fluid from the GI tract are known as lacteals. Embryology The development of the lymphatic system is known from both human and animal, especially mouse studies. The lymphatic vessels form after the development of blood vessels, around six weeks post-fertilization. The endothelial cells that serve as precursors to the lymphatics arise from the embryonic cardinal veins. The process by which lymphatic vessels form is similar to that of the blood vessels and produces lymphatic-venous and intra-lymphatic anastomoses, but diverse origins exist for components of lymphatic vessel formation in different regions.  Six primary lymph sacs develop and are apparent about eight weeks post-fertilization. These include, from caudal to cranial, one cisterna chyli, one retroperitoneal lymph sac, two iliac lymph sacs, and two jugular lymph sacs. The jugular lymph sacs are the first to develop, initially appearing next to the jugular part of the cardinal vein. Lymphatic vessels then form adjacent to the blood vessels and connect the various lymph sacs. The lymphatic vessels primarily arise from the lymph sacs through the process of self-proliferation and polarized sprouting.  Stem/progenitor cells play a huge role in forming lymphatic tissues and vessels by contributing to sustained growth and postnatally differentiating into lymphatic endothelial cells. Lymphatic channels from the developing gut connect with the retroperitoneal lymph sac and the cisterna chyli, situated just posteriorly. The lymphatic channels of the lower extremities and inferior trunk communicate with the iliac lymph sacs. Finally, lymphatic channels in the head, neck and upper extremities drain to the jugular lymph sacs. Additionally, a right and left thoracic duct form and connect the cisterna chyli with the jugular lymph sacs and form anastomoses that eventually produce the typical adult form. The lymph sacs then produce groups of lymph nodes in the fetal period. Migrating mesenchyme enters the lymph sacs and produces lymphatic networks, connective tissue, and other layers of the lymph nodes. Function The lymphatic system's primary function is to balance the volume of interstitial fluid and convey it and excess protein molecules into the venous circulation. The lymphatic system is also important in immune surveillance, defending the body against foreign particles and microorganisms. It does so by conveying antigens and leukocytes to lymph nodes, where antigen-primed and targeted lymphocytes and other immune cells are conveyed into the lymphatic vessels and blood vessels. In addition, the system has a role in the absorption of fat-soluble vitamins and fatty substances in the gut via the gastrointestinal tract's lacteals within the villi and the transport of this material into the venous circulation.  Newly recognized lymphatic vessels are visible in the meninges relating to cerebrospinal fluid (CSF) outflow from the central nervous system. Finally, lymphatics may play a role in the clearance of ocular fluid via the lymphatic-like Schlemm canals. Clinical Significance Leaks of lymphatic fluid occur when the lymphatic vessels are damaged. In the abdomen, lymphatic vessel damage may occur during surgery, especially during retroperitoneal procedures such as repairing an abdominal aortic aneurysm. These leaks tend to be mild, and the vessels in the peritoneum and mesentery eventually absorb the lymphatic fluid or chyle. However, when the thoracic duct is injured in the chest, the chyle leak can be extensive. In most cases, conservative care with a no-fat diet (medium chain triglycerides) or total parenteral nutrition is unsuccessful. In most cases, if the injury to the thoracic duct was surgical, a surgical procedure is required to tie off the duct. If the thoracic duct is injured in the cervical region, then inserting a drainage tube and adopting a low-fat diet will help seal the leak. However, thoracic duct injury in the chest cavity usually requires drainage and surgery. It is rare for the thoracic segment of the thoracic duct to seal on its own. In terms of accumulation of chyle in the thorax (i.e., chylothorax), if a patient has an injury to the thoracic duct in the thorax below the T5 vertebral level, then fluid will collect in only the right pleural cavity. If the injury is to the thoracic duct in the thorax above the T5 vertebral level, then fluid will appear in both pleural cavities.   Other Issues The lymphatic system is prone to disorders like the venous and arterial circulatory systems. Developmental or functional defects of the lymphatic system cause lymphedema. When this occurs, the lymphatic system is unable to sufficiently drain lymphatic fluid resulting in its accumulation and swelling of the territory. Lymphedema, this swelling due to the accumulation of lymph, is classified as primary or secondary. Primary lymphedema is an inherited disorder where the lymphatic system development has been disrupted, causing absent or malformed lymphatic tissues. This condition often presents soon after birth, but some conditions may present later in life (e.g., at puberty or later adulthood). There are no effective treatments for primary lymphedema. Past surgical treatments were found to be mutilating and are no longer implemented. The present-day treatment revolves around compression stockings, pumps, and constrictive garments. Secondary lymphedema is an acquired disorder involving lymphatic system dysfunction that may result from many causes, including cancer, infection, trauma, or surgery. The treatment of secondary lymphedema depends on the cause. Oncological and other surgeries may result in secondary lymphedema due to the removal or biopsy of lymph nodes or lymphatic vessels. Non-surgical lymphedema may result from malignancies, obstruction within the lymphatic system, infection, or deep vein thrombosis. In most cases of obstructive secondary lymphedema, the drainage will resume if the inciting cause is removed, although some individuals may need to wear compressive stockings permanently. Also, physical therapy may help alleviate lymphedema when the extremities are involved. There is no absolute cure for lymphedema, but diagnosis and careful management can help to minimize complications. Lymphomas are cancers that arise from the cells of the lymphatic system. There are numerous types of lymphoma, but they are grouped into Hodgkin lymphoma and non-Hodgkin lymphoma. Lymphomas usually arise from the malignant transformation of specific lymphocytes in the lymphatic vessels or lymph nodes in the gastrointestinal tract, neck, axilla, or groin. Symptoms of lymphoma may include night sweats, fever, fatigue, itching, and weight loss. Cancers originating outside of the lymphatic system often spread via the lymphatic vessels and may involve regional lymph nodes serving the impacted organs or tissues. Lymphadenitis occurs when the lymph nodes become inflamed or enlarged. The cause is usually an adjacent bacterial infection but may also involve viruses or fungi. The lymph nodes usually enlarge and become tender. Lymphatic filariasis, or elephantiasis, is a very common mosquito-borne disorder caused by a parasite found in tropical and subtropical areas of the world, including Africa, Asia, the Pacific, the Caribbean, and South America. This condition involves parasitic microscopic nematodes (roundworms) that infect the lymphatic system and rapidly multiply and disrupt lymphatic function. Many infected individuals may have no outward symptoms, although the kidneys and lymphatic tissues may be damaged and dysfunctional. Symptomatic individuals may present with disfigurement caused by significant lymphedema and elephantiasis (thickening of the skin, particularly the extremities). The parasite may also cause hydrocele, an enlargement of the scrotum due to the accumulation of fluid, which may result from obstruction of the lymph nodes or vessels in the groin. Individuals presenting with symptoms have poorly draining lymphatics, often involving the extremities, resulting in huge extremities and marked disability. Lymphatic filariasis is the most common cause of disfigurement in the world, and it is the second most common cause of long-term disability.  (credits: NIH)

In this Review Series episode, Blood Associate Editor, Dr. Elisabeth Battinelli discusses the Platelet Heterogeneity with authors Drs. Craig Morrell, Larry Frelinger, and Leo Nicolai.  Find the full review series in volume 146 issue 24 of Blood. 

In this special episode, Blood editor Dr. Laura Michaelis interviews Dr. Arielle Langer and Blood Associate editor Dr. Marc Blondon for this special Maternal Health episode. In honor of the second Maternal Health compendium, both discuss their papers featured in this special collection. Featured Articles: β-Thalassemia minor is associated with high rates of worsening anemia in pregnancyLongitudinal profile of estrogen-related thrombotic biomarkers after cessation of combined hormonal contraceptivesSee the entire Maternal Health Compendium Second Edition

We grant our third Christmas Wish to Tiffany, whose husband Derrick has been dealing with heart issues for years and has recently been diagnosed with Lymphoma. Thanks to Treasure Island Resort & Casino and Holiday Station Stores. DONATE to Christmas Wish: www.kdwb.com/wish.See omnystudio.com/listener for privacy information.

We grant our third Christmas Wish to Tiffany, whose husband Derrick has been dealing with heart issues for years and has recently been diagnosed with Lymphoma. Thanks to Treasure Island Resort & Casino and Holiday Station Stores. DONATE to Christmas Wish: www.kdwb.com/wish.

To have Dr. Morse answer a question, visit: https://drmorses.tv/ask/   00:00:00 - Intro - Vaccination Study https://handcraftedbotanicalformulas.com/study-henry-ford-health-system/ 00:06:58 - Panic Attacks - Anxiety - Fear of Death  00:39:00 - Seizure 00:48:10 - Thyroid Nodules 00:56:15 - Type 2 Lymphoma 01:19:49 - Tremors - Head Pressure - Mental Health Problems - Insomnia - Depression 01:46:34 - Chronic Fatigue - Update with Eyes 00:06:58 - Panic Attacks - Anxiety - Fear of Death  I have been born with aneurysm of the interatrial septum. 00:39:00 - Seizure Do I wean off this medication? 00:48:10 - Thyroid Nodules I got scared and did a biopsy. 00:56:15 - Type 2 Lymphoma Tumor on his spine that has 'spread' into the inner spine. He's in severe pain. 01:19:49 - Tremors - Head Pressure - Mental Health Problems - Insomnia - Depression No one can understand what is happening, my brain is literally burning. 01:46:34 - Chronic Fatigue - Update with Eyes Despite a lot of change, still suffering from chronic fatigue.

Dr. Monty Pal and Dr. Jason Westin discuss the federal funding climate for cancer research and the persistent problem of drug shortages, two of the major concerns facing the oncology community in 2026. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I am your host, Dr. Monty Pal. I am a medical oncologist and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. There are always multiple challenges facing oncologists, and today, we discuss two of them that really stand out for 2026: threats to federal funding for cancer research and the persistent problem of drug shortages. I am thrilled to welcome Dr. Jason Westin, who believes that one way to meet these challenges is to get oncologists more involved in advocacy, and he will share some strategies to help us meet this moment in oncology. Dr. Westin is a professor in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center, but he actually wears a lot of hats within ASCO. He is a member of the Board of Directors and has also previously served as chair of ASCO's Government Relations Committee. And he is also one of the inaugural members of ASCO's Political Action Committee, or PAC. He has testified before Congress about drug shortages and many other issues. Dr. Westin, I am really excited to have you on the podcast today and dive into some of these elements that will really impact our community in 2026. Thanks so much for joining us today. Dr. Jason Westin: Thank you for having me. Dr. Monty Pal: You've had such a range of experience. I already alluded to you testifying before Congress. You've actually run for office before. You wear so many different hats. I'm used to checking my PubMed every other day and seeing a new paper out from you and your group, and you publish in the New England Journal [of Medicine] on practice-setting standards and the diseases that you treat. But you've also done all this work in the domain of advocacy. I can't imagine that balancing that is easy. What has sort of motivated you on the advocacy front? Dr. Jason Westin: Advocacy to me is another way to apply our skills and help more people than just those that you're sitting across from at the time. Clinical research, of course, is a tool to try and take what we know and apply it more broadly to people that you'll never meet. And advocacy, I think, can do the same thing, where you can have a conversation with a lawmaker, you can advocate for a position, and that hopefully will help thousands or maybe even more people down the road who you'd never get to directly interact with. And so, I think it's a force multiplier in the same way that research can be. And so, I think advocacy is a wonderful part of how doctors care for our patients. And it's something that is often difficult to know where to start, but once people get into advocacy, they can see that the power, the rewarding nature of it is attractive, and most people, once they get going, continue with that through the rest of their career. Dr. Monty Pal: So, I'll ask you to expand on that a little bit. We have a lot of our younger ASCO members listening to this podcast, folks that are just starting out their careers in clinical practice or academia. Where does that journey begin? How do you get to the point that you're testifying in front of Congress and taking on these bigger sort of stances for the oncology community? Dr. Jason Westin: Yeah, with anything in medicine and in our careers, you have to start somewhere. And often you start with baby steps before you get in front of a panel of senators or other high-profile engagement opportunities. But often the first setting for junior colleagues to be engaged is doing things – we call them "Hill Days" – but basically being involved in kind of low-stakes meetings where you're with a group of peers, some of whom have done this multiple times before, and can get engaged talking to members of representatives' offices, and doing so in a way where it's a natural conversation that you're telling a story about a patient in your clinic, or that you're telling a personal experience from a policy that impacted your ability to deliver optimal care. It sounds stressful, but once you're doing it, it's not stressful. It's actually kind of fun. And it's a way that you can get comfort and skill with a group of peers who are there and able to help you. And ASCO has a number of ways to do that, both at the federal level, there's the Hill Day where we each April have several hundred ASCO members travel to Capitol Hill. There's also state engagement that can be done, so-called visiting at home, when representatives from the U.S. Congress or from state legislators are back in district. You can meet with your own representatives on behalf of yourself, on behalf of your organization, and advocate for policies in a way that can be beneficial to your patients. But those initial meetings that are in the office often they're low stakes because you could be meeting not with the representative but with their staff. And that staff sometimes is as young or even younger than our junior colleagues. These sometimes can be people in their 20s, but they're often extremely knowledgeable, extremely approachable, and are used to dealing with people who are new to advocacy. But they actually help make decisions within the office. So it's not a waste of time. It's actually a super useful way to engage. So, it's that first step of anything in life. The activation energy is always high to do something new. But I'd encourage people who are listening to this podcast already having some level of interest about it to explore ways that they could engage more. Dr. Monty Pal: You know, I have to tell you, I'm going to riff on what you just said for a second. ASCO couldn't make it any easier, I think, for folks to participate and get involved. So, if you're listening to this and scratching your head and thinking, "Well, where do I begin? How do I actually sign on for that meeting with a local representative?" Go to the ASCO ACT Network website. And I'll actually talk to our producer, Geraldine, to make sure we've got a link to that somewhere associated with this podcast after it's published, Jason, but I actually keep that on my browser and it's super easy. I check in there every now and then and see if there's any new policy or legislation that ASCO, you know, is sort of taking a stance on, and it gives me some fodder for conversation with my local representatives too. I mean, it's just an awesome, awesome vehicle. I'm going to segue right from there right to the issues. So, you and I are both at academic centers. You know, I think this is something that really pervades academia and enters into implications for general clinical practice. There's been this, you know, massive sort of proposal for decreased funding to the NCI and to the NIH and so forth. Tell us what ASCO is doing in that regard, and tell us perhaps how our community can help. Dr. Jason Westin: We live in interesting times, and I think that may be an understatement x 100. But obviously investments in research are things that when you're at an academic center, you see and feel that as part of your daily life. Members of Congress need to be reminded of that because there's a lot of other competing interests out there besides investing in the future through research. And being an elected representative is a hard job. That is something where you have to make difficult choices to support this, and that may mean not supporting that. And there's lots of good things where our tax dollars could be spent. And so, I'm sympathetic to the idea that there's not unlimited resources. However, ASCO has done an excellent job, and ASCO members have led the charge on this, of stating what research does, what is the benefit of research, and therefore why should this matter to elected representatives, to their staff, and to those people that they're elected to serve. And ASCO has led with a targeted campaign to basically have that message be conveyed at every opportunity to elected representatives. And each year on Hill Day, one of the asks that we have is to continue to support research: the NCI, NIH, ARPA-H, these are things that are always in the asks to make sure that there's appropriate funding. But effectively playing offense by saying, "It's not just a number on a sheet of paper, this is what it means to patients. This is what it means to potentially your loved ones in the future if you are in the opposite situation where you're not on the legislative side, but you're in the office receiving a diagnosis or receiving a difficult piece of news." We only have the tools we have now because of research, and each breakthrough has been years in the making and countless hours spent funded through the engine of innovation: clinical research and translational research. And so ASCO continues to beat that drum. You mentioned earlier the ACT Network. Just to bring that back again is a very useful, very easy tool to communicate to your elected representatives. When you sign up on the ASCO ACT website, you get emails periodically, not too much, but periodically get emails of, "This is a way you can engage with your lawmakers to speak up for this." And as you said, Monty, they make it as easy as possible. You click the button, you type in your address so that it figures out who your elected representatives are, and then it will send a letter on your behalf after like five clicks to say, "I want you to support research. I want you to vote for this particular thing which is of interest to ASCO and by definition to members of ASCO." And so the ACT Network is a way that people listening can engage without having to spend hours and significant time, but just a few clicks can send that letter to a representative in Congress. And the question could be: does that matter? Does contacting your senator or your elected representative do anything? If all they're hearing is somebody else making a different argument and they're hearing over and over again from people that want investments in AI or investments in something else besides cancer research, whatever it is, they may think that there's a ground shift that people want dollars to be spent over here as opposed to at the NIH or NCI or in federally funded research. It is important to continue to express the need for federal funding for our research. And so, it really is important for folks to engage. Dr. Monty Pal: 100%. One of the things that I think is not often obvious to a lot of our listeners is where the support for clinical trials comes from. You know, you've obviously run the whole gamut of studies as have I. You know, we have our pharmaceutical company-sponsored studies, which are in a particular bucket. But I would say that there's a very important and critical subset of studies that are actually government funded, right? NCI-funded clinical trials. If you don't mind, just explain to our audience the critical nature of the work that's being done in those types of studies and if you can, maybe compare and contrast the studies that are done in that bucket versus perhaps the pharmaceutical bucket. Dr. Jason Westin: Both are critical, and we're privileged that we have pharma studies that are sponsored and federally funded clinical research. And I think that part of a healthy ecosystem for us to develop new breakthroughs has a need for both. The pharma sponsored studies are done through the lens of trying to get an approval for an agent that's of interest so that the pharma company can then turn around and use that outside of a clinical trial after an FDA approval. And so those studies are often done through the lens of getting over the finish line by showing some superiority over an existing treatment or in a new patient population. But they're done through that lens of kind of the broadest population and sometimes relatively narrow endpoints, but to get the approval so that then the drug can be widely utilized. Clinical trials done through cooperative groups are sometimes done to try and optimize that or to try and look at comparative things that may not be as attractive to pharma studies, not necessarily going for that initial approval, but the fine tuning or the looking at health outcomes or looking at ensuring that we do studies in representative populations that may not be as well identified on the pharma sponsored trials, but basically filling out the gaps in the knowledge that we didn't gain from the initial phase 3 trial that led to the approval. And so both are critical. But if we only do pharma sponsored trials, if we don't fund federally supported research and that dries up, the fear I have, and many others have, is that we're going to be lacking a lot of knowledge about the best ways to use these great new therapies, these new immune therapies, or in my team, we do a lot of clinical trials on CAR T-cell therapies. If we don't have federally funded research to do the important clinical studies, we'll be in the dark about the best ways to use these drugs, and that's going to be a terrible shame. And so we really do need to continue to support federal research. Dr. Monty Pal: Yeah, there are no softball questions on this podcast, but I think everybody would be hard pressed to think that you and I would come on here and say, "Well, no, we don't need as much money for clinical trials and NCI funding" and so forth. But I think a really challenging issue to tackle, and this is something we thought to ask you ahead of the podcast, is what to do about the general climate of, you know, whether it's academic research or clinical practice here that seems to be getting some of our colleagues thinking about moving elsewhere. I've actually talked to a couple of folks who are picking up and moving to Europe for a variety of considerations, other continents, frankly. The U.S. has always been a leader when it comes to oncology research and, one might argue, research in general. Some have the mindset these days that we're losing that footing a little bit. What's your perspective? Are you concerned about some of the trends that you're seeing? What does your crystal ball tell you? Dr. Jason Westin: I am highly concerned about this. I think as you said, the U.S. has been a leader for a long time, but it wasn't always. This is not something that's preordained that the world-leading clinical research and translational research will always be done in the United States. That is something that has been developed as an ecosystem, as an engine for innovation and for job development, new technology development, since World War II. That's something that through intentional investments in research was developed that the best and brightest around the world, if they could choose to go anywhere, you wanted them to come to work at universities and academic places within the United States. And I think, as you said, that's at risk if you begin to dry up the investment in research or if you begin to have less focus on being engaged in research in a way that is forward thinking, not just kind of maintaining what we do now or only looking at having private, for profit sponsored research. But if you don't have the investment in the basic science research and the translational research and the forward-thinking part of it, the fear is that we lose the advantage and that other countries will say, "Thank you very much," and be happy to invest in ways to their advantage. And I think as you mentioned, there are people that are beginning to look elsewhere. I don't think that it's likely that a significant population of researchers in the U.S. who are established and have careers and families – I don't think that we're going to see a mass exodus of folks. I think the real risk to me is that the younger, up-and-coming people in undergraduate or in graduate school or in medical school and are the future superstars, that they could either choose to go into a different field, so they decide not to go into what could be the latest breakthroughs for cancer patients but could be doing something in AI or something in a different field that could be attractive to them because of less uncertainty about funding streams, or they could take that job offer if it's in a different country. And I think that's the concern is it may not be a 2026 problem, but it could be a 2036 or a 2046 problem that we reap what we sow if we don't invest in the future. Dr. Monty Pal: Indeed, indeed. You know, I've had the pleasure of reviewing abstracts for some of our big international meetings, as I'm sure you've done in the past too. I see this trend where, as before, we would see the preponderance of large phase 3 clinical trials and practice setting studies being done here in the U.S., I'm seeing this emergence of China, of other countries outside of the U.S. really taking lead on these things. And it certainly concerns me. If I had to sort of gauge this particular issue, it's at the top of my list in terms of what I'm concerned about. But I also wanted to ask you, Jason, in terms of the issues that are looming over oncology from an advocacy perspective, what else really sort of keeps you up at night? Dr. Jason Westin: I'm quite concerned about the drug shortages. I think that's something that is a surprisingly evergreen problem. This is something that is on its face illogical that we're talking about the greatest engine for research in the world being the United States and the investment that we've made in drug development and the breakthroughs that have happened for patients all around the world, many of them happen in the United States, and yet we don't necessarily have access to drugs from the 1970s or 1980s that are cheap, generic, sterile, injectable drugs. This is the cisplatins and the vincristines and the fludarabine type medications which are not the sexy ones that you see the ads in the magazine or on TV at night. These are the backbone drugs for many of our curative intent regimens for pediatrics and for heme malignancies and many solid tumors. And the fact that that's continuing to be an issue is, in my opinion, a failure to address the root causes, and those are going to require legislative solutions. The root causes here are basically a race to the bottom where the economics to invest in quality manufacturing really haven't been prioritized. And so it's a race to the cheapest price, which often means you undercut your competitor, and when you don't have the money to invest in good manufacturing processes, the factory breaks down, there's no alternative, you go into shortage. And this has been going on for a couple of decades, and I don't think there's an end in sight until we get a serious solution proposed by our elected officials. That is something that bothers me in the ways where we know what we should be doing for our patients, but if we don't have the drugs, we're left to be creative in ways we shouldn't have to do to figure out a plan B when we've got curative intent therapies. And I think that's a real shame.  There's obviously a lot of other things that are concerning related to oncology, but something that I have personally had experience with when I wanted to give a patient a CAR T-cell, and we don't have a supply of fludarabine, which is a trivial drug from decades ago in terms of the technology investments in genetically modified T-cells, to not then have access to a drug that should be pennies on the dollar and available at any time you want it is almost like the Air Force investing in building the latest stealth bomber, but then forgetting to get the jet fuel in a way that they can't use it because they don't have the tools that they need. And so I think that's something that we do need to have comprehensive solutions from our elected officials. Dr. Monty Pal: Brilliantly stated. I like that analogy a lot. Let's get into the weeds for a second. What would that proposal to Congress look like? What are we trying to put in front of them to help alleviate the drug shortages? Dr. Jason Westin: We could spend a couple hours, and I know podcasts usually are not set up to do that. And so I won't go through every part. I will direct you that there have been a couple of recent publications from ASCO specifically detailing solutions, and there was a recent white paper from the Senate Finance Committee that went through some legislative solutions being explored. So Dr. Gralow, ASCO CMO, and I recently had a publication in JCO OP detailing some solutions, more in that white paper from the Senate Finance. And then there's a working group actually going through ASCO's Health Policy Committee putting together a more detailed proposal that will be published probably around the end of 2026. Very briefly, what needs to happen is for government contracts for purchasing these drugs, there needs to be an outlay for quality, meaning that if you have a manufacturing facility that is able to deliver product on time, reliably, you get a bonus in terms of your contract. And that changes the model to prioritize the quality component of manufacturing. Without that, there's no reason to invest in maintaining your machine or upgrading the technology you have in your manufacturing plant. And so you have bottlenecks emerge because these drugs are cheap, and there's not a profit margin. So you get one factory that makes this key drug, and if that factory hasn't had an upgrade in their machines in 20 years, and that machine conks out and it takes 6 months to repair or replacement, that is an opportunity for that drug to go into shortage and causes a mad dash for big hospitals to purchase the drug that's available, leaving disparities to get amplified. It's a nightmare when those things happen, and they happen all the time. There are usually dozens, if not hundreds, of drugs in shortage at any given time. And this has been going on for decades. This is something that we do need large, system-wide fixes and that investment in quality, I think, will be a key part. Dr. Monty Pal: Yeah, brilliantly said. And I'll make sure that we actually include those articles on the tagline for this podcast as well. I'll talk to our producer about that as well.  I'm really glad you mentioned the time in your last comment there because I felt like we just started, but in fact, I think we're right at our close here, Jason, unfortunately. So, I could have gone on for a couple more hours with you. I really want to thank you for these absolutely terrific insights and thank you for all your advocacy on behalf of ASCO and oncologists at large. Dr. Jason Westin: Thank you so much for having me. I have enjoyed it. Dr. Monty Pal: Thanks a lot. And many thanks to our listeners too. You can find more information about ASCO's advocacy agenda and activities at asco.org. Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks so much. ASCO Advocacy Resources: Get involved in ASCO's Advocacy efforts: ASCO Advocacy Toolkit Crisis of Cancer Drug Shortages: Understanding the Causes and Proposing Sustainable Solutions, JCO Oncology Practice Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:     Dr. Monty Pal   @montypal   Dr. Jason Westin @DrJasonWestin   Follow ASCO on social media:      @ASCO on X     ASCO on Bluesky    ASCO on Facebook      ASCO on LinkedIn      Disclosures:     Dr. Monty Pal:    Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview   Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical   Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Jason Westin: Consulting or Advisory Role: Novartis, Kite/Gilead, Janssen Scientific Affairs, ADC Therapeutics, Bristol-Myers Squibb/Celgene/Juno, AstraZeneca, Genentech/Roche, Abbvie, MorphoSys/Incyte, Seattle Genetics, Abbvie, Chugai Pharma, Regeneron, Nurix, Genmab, Allogene Therapeutics, Lyell Immunopharma Research Funding: Janssen, Novartis, Bristol-Myers Squibb, AstraZeneca, MorphoSys/Incyte, Genentech/Roche, Allogene Therapeutics

 In this week's episode, Blood editor Dr. James Griffin speaks with Drs. Emanuele Zucca and Sandra Pinho about their latest articles published in Blood. Dr. Zucca discusses his second analysis of the IELSG37 trial, where findings suggested that R-CHOP21 rituximab, cyclophosphamide,doxorubicin, vincristine, and prednisone, administered every 21 days) may be a suboptimal frontline regimen for PMBCL. Dr. Pinho discusses the aging megakaryocytic niche and its influence on the age-associated decline in HSC and progenitor cell function. The authors demonstrate that remodeling of the megakaryocytic niche and associated platelet factor 4 (PF4) downregulation are central mechanisms driving HSC aging.Featured Articles: Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial Platelet Factor 4 (PF4) Regulates Hematopoietic Stem Cell Aging 

We grant our third Christmas Wish to Tiffany, whose husband Derrick has been dealing with heart issues for years and has recently been diagnosed with Lymphoma. Thanks to Treasure Island Resort & Casino and Holiday Station Stores. DONATE to Christmas Wish: www.kdwb.com/wish.See omnystudio.com/listener for privacy information.

In today's episode, we had the pleasure of speaking with Sarah Rutherford, MD, about the evolving role of minimal residual disease (MRD) and circulating tumor DNA (ctDNA) testing for lymphoma treatment decision-making. Dr Rutherford is an associate professor of clinical medicine in the Division of Hematology/Oncology at Weill Cornell Medicine in New York, New York.  In our exclusive interview, Dr Rutherford discussed the usefulness of ctDNA for guiding patient treatment, clinical trials that are ongoing to determine the best use of this type of assay, how personalized ctDNA testing offers the potential for disease surveillance and effective intervention, key hurdles in the way of widespread implementation of ctDNA testing in clinical practice, and how integration with next-generation sequencing is expected to further tailor treatment strategies.

Today's guest is Erin Cummings, co-founder and executive director of Hodgkin's International, a non-profit dedicated to supporting, educating, and advocating for long-term survivors of Hodgkin's Lymphoma Worldwide. She herself is an over 50 year survivor of Hodgkin's Lymphoma. Erin believes that survivorship is not the end of the cancer journey, but a lifelong chapter that deserves understanding, resources and hope.We talk all about Hodgkin's Lymphoma, treatments that are thankfully no longer in practice, what are called "late effects" of those treatments, the importance of survivorship care and community, pro-active health management, and so much more!!Resources:Erin's Website: https://www.hodgkinsinternational.com/Erin's Facebook:  https://www.facebook.com/hodgkinsurvivorsErin's Linkedin: https://www.linkedin.com/company/hodgkins-internationalErin's Instagram: https://www.instagram.com/hodgkinsinternational/Erin's Email: erincummings@hodgkinsinternational.orgFollow:Follow me: https://www.instagram.com/melissagrosboll/My website: https://melissagrosboll.comEmail me: drmelissagrosboll@gmail.com

In this week's episode, Blood editor Dr. Laurie Sehn interviews authors Drs. Lorenzo Falchi and Robert Levy on their latest papers published in Blood Journal. Dr. Falchi discusses his work on an open-label, multicenter phase 1b/2 study evaluating fixed-duration epcoritamab with rituximab and lenalidomide in 108 patients with relapsed or refractory follicular lymphoma. Dr. Levy shares his work on demonstrating that in vivo expansion of Tregs in recipients prior to transplant is possible by activating TNFRSF25 (also known as death receptor 3) in combination with low-dose interleukin-2 in preclinical models. Both papers showed impressive and promising results for the treatment of lymphoma and GVHD.Featured ArticlesFixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular LymphomaPre-transplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues ameliorating GVHD post-HSCT

Ever wondered what happens when you take the leadership lessons from flying military helicopters and apply them to corporate America? In this conversation with Carl Sharperson Jr., author of "Sharp Leadership" and former Marine Corps pilot, Cam and Otis explore the fascinating transition from military service to business leadership."The plant ran better with us not being there than it did when we were there," Carl reveals, sharing a powerful story about what happened when all the managers went on a two-day retreat. This counterintuitive insight highlights one of Carl's core leadership principles: when you truly empower your people with the right tools and resources, they'll often exceed your expectations.What makes this episode particularly valuable is Carl's candid reflection on his own leadership journey. "My team leader pulled me aside one day and said, 'Carl, you're micromanaging, you don't need to do that,'" he shares, explaining how this direct feedback helped him "flip the script" and transform his approach. From discussing the delicate balance of allowing people to fail without catastrophic consequences to exploring how he applied leadership principles as an entrepreneur, Carl offers practical wisdom drawn from his unique experience across military, corporate, and entrepreneurial settings.Whether you're transitioning from one leadership context to another or simply looking to elevate your team from mediocrity to excellence, Carl's insights on building relationships and taking care of your people provide a roadmap for authentic, effective leadership.More About Carl:Carl Sharperson Jr. is a renowned Leadership Innovation Strategist, speaker, and coach, celebrated for his ability to elevate leaders from mediocrity to their fullest potential in both professional and personal realms. He is the acclaimed author of Sharp Leadership: Overcome Adversity to Lead with Authenticity and Sharp Leadership: Parenting Principles for Rearing Young People. Carl's expertise lies in recognizing that many individuals operate at only 50% capacity due to inadequate leadership, development, or job fit. Through his proprietary Sharp Leadership coaching process, combined with his rich experiences in the military, corporate America, and entrepreneurship, Carl delivers transformative results for his audiences and corporate clients. A proud graduate of the United States Naval Academy and a former United States Marine Corps pilot with a BS in Engineering, Carl has also documented his military experiences in Short Rations for Marines and For My Sons and Brothers. Following his distinguished military service, Carl held senior sales and operational positions at prestigious companies such as Procter & Gamble, Frito-Lay, and Colgate-Palmolive. He was Vice President of Manufacturing for an international sports company before answering the call to entrepreneurship in 2000, launching Sharperson's Executive Leadership. Carl has since worked with executives at major organizations, including Purdue Farms, Harley-Davidson, GlaxoSmithKline, Sara Lee, BMW, Edward Jones, Houston Independent School District, Lockheed Martin, Honeywell, the University of North Carolina, and Chick-fil-A, among others. As a dynamic speaker, Carl travels nationwide, inspiring students to explore military training, sharing his triumphant journey of surviving Stage 4 Non-Hodgkin's Lymphoma and Stage 1 Colon cancer, and empowering leaders with the principles of servant leadership. Dedicated to giving back, Carl actively participates in several community and faith-based initiatives, mentoring youth and helping them reach their maximum potential. He resides in the Upstate of South Carolina with his wife, and they are proud parents of a son and a daughter. If you are ready to elevate your team from mediocrity to excellence, book Carl Sharperson Jr. today.Chapter Times and Titles:From CH-46 to Corporate America [00:00 - 05:00

On this episode of Bringin' It Backwards, host Adam Lisicky reconnects with Caroline Grace Vein (Blondestandard) for an honest, inspiring conversation about resilience, creativity, and the journey of an artist. Nearly three years after her breakthrough debut "Blue Eyes," Caroline opens up about navigating health challenges—including a diagnosis of Hodgkin's lymphoma just after graduating college—and how they shaped her music and perspective. She shares how those experiences led to a deeper, more authentic songwriting process, the evolution of her sound from bubblegum pop to alternative rock, and the impact of community and collaboration in her work. Caroline dives into the stories behind new singles like "California Dreams," "Freaking Out," "Ruin My Day," and her latest release, "Arms of Another," offering insight into the themes of vulnerability, strength, and connection that drive her artistry. Plus, Caroline reveals she's working on a new podcast to share her story even further, and gives advice to fellow aspiring musicians: stay true to yourself, focus on what you love, and let your art resonate authentically. Whether you're an indie musician, a fan of genuine artist stories, or looking for inspiration to overcome obstacles and pursue your passion, this episode is full of raw, empowering moments you won't want to miss. Listen to the full interview and be sure to subscribe to Bringin' It Backwards for more stories from legendary and rising artists!

Real progress comes when we stop managing symptoms and start understanding the body's messages. What might yours be saying?In this episode, I sit down with Dr. Erin Ellis, a naturopathic doctor whose own health journey from Non-Hodgkin lymphoma to Hashimoto's completely reshaped how she approaches healing. We talk about her path from cancer survivor to women's hormone specialist, and how she uncovered the deeper connections between thyroid autoimmunity, toxins, and genetic vulnerability. Dr. Ellis shares what helped her reverse Hashimoto's antibodies, the foundational steps she teaches her patients, and why true recovery often begins with something as simple as sleep, food quality, and reducing toxic load. Her story is a powerful reminder that the body can heal when we understand why it's reacting, not just how to suppress symptoms.This conversation might help you see your symptoms in a completely new way. Listen now!Episode Timeline: 00:00 – Episode Preview01:20 – Podcast Intro01:44 – Cancer Journey and Motivation02:22 – Why She Focused on Women's Hormones03:40 – The Hashimoto's Diagnosis Story06:16 – Cancer Recurrence and Turning Point14:03 – Hashimoto's Antibodies Turn Negative14:16 – Role of Low-Dose Naltrexone (LDN)15:13 – Gluten, Diet, and Antibody Response16:09 – Oxidative Stress and Glyphosate Link18:43 – Ongoing Detox and IV Glutathione20:31 – Lymphatic Massage and Detox Support24:01 – Sauna, Red Light, and Cold Plunge27:00 – Parasite Cleansing Experience28:24 – Full Thyroid and Hormone Panels30:20 – Starting with Foundational Habits33:35 – Final Advice on Listening to Your Body35:21 – Where to Find Dr. Ellis36:21 – Episode Wrap-Up and Outro36:41 – Dr. Eric's Reflection and TakeawaysAbout Dr. Erin Ellis: Dr. Erin Ellis is a Naturopathic Doctor who helps women balance hormones, improve menstrual health, and regain the energy they once had. After being diagnosed with a rare form of Non-Hodgkin's Lymphoma in 2010, she turned that experience into the motivation to pursue natural medicine. Her journey shaped a mission to help others take control of their health and understand that the body has an innate ability to heal when given the right tools. Life, as she often says, is too short to feel suboptimal. Outside of her work, Dr. Ellis enjoys tim Free resources for your thyroid health Get your FREE Thyroid and Immune Health Restoration Action Points Checklist at SaveMyThyroidChecklist.com High-Quality Nutritional Supplements For Hyperthyroidism and Hashimoto' s Have you checked out my new ThyroSave supplement line? These high-quality supplements can benefit those with hyperthyroidism and Hashimoto's, and you can receive special offers, along with 10% off your first order, by signing up for emails and text messages when you visit ThyroSave.com. Do You Want Help Saving Your Thyroid? Get free access to hundreds of articles and blog posts: https://www.naturalendocrinesolutions.com/articles/all-other-articles Watch Dr. Eric's YouTube channel: https://www.youtube.com/c/NaturalThyroidDoctor/videos Join Dr. Eric's Graves' disease and Hashimoto's group: https://www.facebook.com/groups/saveyourthyroid Take the Thyroid Saving Score Quiz: https://quiz.savemythyroidquiz.com/sf/237dc308 ...